Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

Completed · Phase 3

Conditions studied: Acute Myeloid Leukemia

In brief

The purpose of this study is to assess the feasibility and efficacy of a novel form of therapy-haploidentical NK cell transplantation-in patients with standard-risk AML. In addition, we will investigate the efficacy of clofarabine + cytarabine (Clo/AraC) in newly diagnosed patients with AML and attempt to optimize outcome through the use of MRD-adapted therapy and further improvements in supportive care.

Key facts

Study ID

NCT00703820

Run by

St. Jude Children's Research Hospital

People needed

324

Starts

2008-08-04

Expected to finish

2020-08-14

Last updated by the study team

2021-08-10

Who can join

Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age less than or equal to 21 years at time of study entry.
• No prior therapy for this malignancy except for one dose of intrathecal therapy and the use of hydroxyurea or low-dose cytarabine (100-200 mg/m2 per day for one week or less ) for hyperleukocytosis.
• Written informed consent according to institutional guidelines
• Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment
• Male and female participants must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.

You may not qualify if…

• Down syndrome
• Acute Promyelocytic Leukemia (APL)
• Juvenile Myelomonocytic Leukemia (JMML)
• Fanconi anemia (FA)
• Kostmann syndrome
• Shwachman syndrome
• Other bone marrow failure syndromes
• Use of concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.
• Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of IT therapy, hydroxyurea, or low-dose cytarabine as stated above. The patient must have recovered from all acute toxicities from any previous therapy.
• Systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
• Pregnant or lactating patients.
• Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.

Where it is running

• Stanford University Medical Center — Palo Alto, California, United States
• Rady Children's Hospital — San Diego, California, United States
• University of Chicago — Chicago, Illinois, United States
• Dana Farber Cancer Institute and Children's Hospital — Boston, Massachusetts, United States
• Children's Hospital of Michigan — Detroit, Michigan, United States
• St. Jude Children's Research Hospital — Memphis, Tennessee, United States
• Cook's Children's Medical Center — Fort Worth, Texas, United States
• National University Health System — Singapore, Singapore

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.